Every Major Review Points The Same Way: E-Cigarettes May Help Smokers Quit

Quitting smoking is one of the hardest things a person can do. Patches, gums, and counseling all have their advocates, but a sweeping new analysis suggests that for smokers, the device that most resembles a cigarette may also be one of the more effective tools for quitting.

Published in the journal Addiction, the analysis gathered 14 separate systematic reviews, the most rigorous form of medical evidence, and tallied every statistical comparison they contained on whether nicotine e-cigarettes help adults stop smoking for at least six months. Across 21 such comparisons, every estimate leaned in favor of nicotine e-cigarettes over the alternatives, though not all results were statistically clear-cut.

Conducted by researchers at the University of Oxford and several collaborating institutions, this marks the first “overview of reviews” paired with an interactive evidence map dedicated to e-cigarettes and smoking cessation. Rather than running a new experiment, the team collected every qualifying review published since 2015, graded each for quality, and compared the results. Whether the alternative was nicotine patches, placebo vapes, counseling alone, or nothing at all, quit rates pointed in the same direction every time.

What the E-Cigarette Smoking Cessation Data Showed

Researchers searched seven major medical databases through April 2024. Each qualifying review was graded using a standardized checklist. Seven of the 14 earned a “higher quality” rating; the other seven were classified as “lower quality,” typically for missing documentation, inadequate bias controls, or skipped checks for publication bias.

Against nicotine replacement therapy, including patches, gums, and lozenges, higher-quality reviews found e-cigarette users were roughly 1.58 to 1.59 times as likely to quit. Against placebo e-cigarettes, devices identical in appearance and feel but containing no nicotine, the advantage was larger. One analysis covering 16 studies and more than 3,800 participants found nicotine e-cigarette users were about 2.37 times as likely to have quit. Against behavioral support alone, such as counseling or quit-line calls, a higher-quality review of nine studies and more than 5,000 participants found e-cigarette users were 1.88 times as likely to have stopped smoking at the six-month mark or later. These estimates varied in certainty, and some included the possibility of little or no difference.

Perhaps the most notable number involved combination therapy. Based on a limited set of studies, when nicotine e-cigarettes were added on top of traditional nicotine replacement therapy and then compared against nicotine replacement therapy alone, quitters in the combination group were 3.53 times as likely to have succeeded.

One comparison ran the other direction. A single trial of just 54 participants suggested that varenicline, a prescription stop-smoking medication, might outperform e-cigarettes. Researchers flagged that study as having a high risk of bias and significant data inconsistencies, making firm conclusions impossible from that comparison alone.

E-Cigarettes and Smoking Cessation: The Safety Question

On safety, the picture is less settled. For everyday side effects such as coughs, throat irritation, and headaches, pooled estimates from multiple reviews generally showed little or no difference between nicotine e-cigarettes and other quit methods, though confidence in some of those findings was low.

Serious adverse events, hospitalizations and life-threatening complications, proved harder to measure. Of 13 reviews that analyzed these outcomes, two reported estimates suggesting a possible increase among e-cigarette users. Nearly every statistical range, however, was wide enough to include the possibility of no difference at all. Rare events are inherently difficult to study, and most of the included trials did not enroll enough participants to detect a meaningful signal. One lower-quality review that did find a notable increase in serious events acknowledged that none of those events were directly connected to e-cigarette use.

Major Gaps in E-Cigarette Research Still Need Filling

Beyond all that, the team also built an interactive evidence map of 90 completed studies, and that wider view revealed significant holes. No studies have compared nicotine e-cigarettes against cytisine, a plant-based quit-smoking drug used in parts of Europe and Asia, or against bupropion, an antidepressant sometimes prescribed to help people quit. Comparisons involving different flavors, device types, and nicotine formulations were also thin on the ground.

More broadly, nearly all the available evidence came from wealthy nations. Low- and middle-income countries, where smoking rates tend to be highest and quitting resources are fewest, are almost entirely absent from the literature.

In their conclusion, the authors argue that the overview and evidence map “can lay to rest some claims that evidence is ‘mixed’ regarding the impacts of ECs on smoking abstinence, given the clear consistency of results across meta-analyses.” For a peer-reviewed paper, that is unusually direct language, and it reflects a frustration that policy debates have sometimes mischaracterized what the science actually shows.

Smoking remains the leading preventable cause of cancer, death, and health inequality globally, and e-cigarettes are not a risk-free product. On the specific question of whether nicotine e-cigarettes help adults who smoke quit for the long haul, 21 out of 21 comparisons pointed in the same direction, even if not all were conclusive.

---

Disclaimer: This article is based on a review of published peer-reviewed research and is not intended as medical advice. Smoking cessation needs vary by individual. Anyone considering changes to a quit-smoking plan should consult a qualified healthcare provider.

---